Please use this identifier to cite or link to this item:
https://hdl.handle.net/10316/102589
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Aguiar, Carlos | - |
dc.contributor.author | Batista, Sónia | - |
dc.contributor.author | Pacheco, Ricardo | - |
dc.date.accessioned | 2022-10-03T10:18:25Z | - |
dc.date.available | 2022-10-03T10:18:25Z | - |
dc.date.issued | 2015-04 | - |
dc.identifier.issn | 08702551 | pt |
dc.identifier.uri | https://hdl.handle.net/10316/102589 | - |
dc.description.abstract | Fingolimod, a structural analogue of sphingosine, is the first oral treatment available for multiple sclerosis. The presence of sphingosine-1-phosphate receptors in the sinus and atrioventricular nodes, myocardial cells, endothelial cells and arterial smooth muscle cells is responsible for fingolimod's cardiovascular effects. We provide a comprehensive review of the mechanisms of these effects and characterize their clinical relevance. | pt |
dc.description.abstract | O fingolimod, um análogo estrutural da esfingosina, é o primeiro tratamento oral disponível para a esclerose múltipla. A presenc¸a de recetores esfingosina-1-fosfato no nódulo sinusal e auriculoventricular, miócitos cardíacos, células endoteliais e células do músculo liso arterial possibilita a ocorrência de efeitos cardiovasculares com o fingolimod. Neste artigo, faz-se uma revisão dos mecanismos dos efeitos cardiovasculares do fingolimod e a caracterização da sua relevância clínica. | pt |
dc.language.iso | eng | pt |
dc.relation | Novartis | pt |
dc.relation | Merck Serono | pt |
dc.relation | Teva | pt |
dc.relation | Biogen | pt |
dc.rights | openAccess | pt |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | pt |
dc.subject | Multiple sclerosis | pt |
dc.subject | Fingolimod | pt |
dc.subject | Bradycardia | pt |
dc.subject | Atrioventricular block | pt |
dc.subject | Heart rate | pt |
dc.subject | Esclerose múltipla | pt |
dc.subject | Fingolimod | pt |
dc.subject | Bradicardia | pt |
dc.subject | Bloqueio auriculoventricular | pt |
dc.subject | Frequência cardíaca | pt |
dc.subject.mesh | Cardiovascular System | pt |
dc.subject.mesh | Fingolimod Hydrochloride | pt |
dc.subject.mesh | Humans | pt |
dc.subject.mesh | Immunosuppressive Agents | pt |
dc.title | Cardiovascular effects of fingolimod: Relevance, detection and approach | pt |
dc.title.alternative | Efeitos cardiovasculares do fingolimod: relevância, deteção e abordagem terapêutica | pt |
dc.type | article | - |
degois.publication.firstPage | 279 | pt |
degois.publication.lastPage | 285 | pt |
degois.publication.issue | 4 | pt |
degois.publication.title | Revista Portuguesa de Cardiologia | pt |
dc.peerreviewed | yes | pt |
dc.identifier.doi | 10.1016/j.repc.2014.11.012 | pt |
degois.publication.volume | 34 | pt |
dc.date.embargo | 2015-04-01 | * |
uc.date.periodoEmbargo | 0 | pt |
item.grantfulltext | open | - |
item.cerifentitytype | Publications | - |
item.languageiso639-1 | en | - |
item.openairetype | article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.fulltext | Com Texto completo | - |
crisitem.author.orcid | 0000-0002-6081-6955 | - |
Appears in Collections: | FMUC Medicina - Artigos em Revistas Nacionais |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
1-s2.0-S0870255115000736-main.pdf | 904.63 kB | Adobe PDF | View/Open |
SCOPUSTM
Citations
10
checked on May 13, 2024
WEB OF SCIENCETM
Citations
7
checked on May 2, 2024
Page view(s)
65
checked on May 7, 2024
Download(s)
42
checked on May 7, 2024
Google ScholarTM
Check
Altmetric
Altmetric
This item is licensed under a Creative Commons License